Louis HawthorneFounder

United States - Mill Valley, California

Lou Hawthorne is the founder and CEO of NaNotics, LLC, and the inventor of the company’s core technology. Lou is an entrepreneur with 25 years of experience in founding and leading companies developing new technologies in biotech/life science and information technology, including reproductive cloning, human IVF, oncology, and artificial intelligence.

In 2002, Lou founded the cloning companies Genetic Savings & Clone and BioArts International, and co-founded Viagen, Inc. acquired by Intrexon (XON) in 2014.

In 2014, Lou conceived "NaNots" – which are subtractive immune modulators – and founded NaNotics LLC, which is currently developing NaNots for treating cancer, sepsis, autoimmune disease and aging, in collaboration with Mayo Clinic. NaNots have demonstrated near total tumor suppression in humanized mouse models of cancer, significantly outperforming checkpoint inhibitors. NaNots are the subject of 29 granted patents to date.

Lou is an experienced company leader with an extensive track record in funding, recruiting and managing senior level multi-disciplinary teams for effective development of new technologies. He has collaborated closely with NaNotics company co-founder, John Dodgson, PhD, a physical chemist and IP expert, for two decades.

Lou is also an expert at brand development and strategic media, having designed global media campaigns that reached millions of people and generated profile valued at hundreds of millions of dollars. He has been interviewed by most major newspapers, magazines, and television programs, including appearances on The Oprah Winfrey Show and Good Morning America.

Lou holds a B.A. in English Literature from Princeton University, where he was a University Scholar and recipient of the Ward Mathis prize.